Succinic Acid-Sunitinib Combination Treatment Downregulates the Angiogenic Gene Expressions in Sunitinib- Resistant Renal Cancer Cell Line
CELL BIOCHEMISTRY AND BIOPHYSICS, cilt.84, sa.3, ss.4395-4407, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 84 Sayı: 3
- Basım Tarihi: 2026
- Doi Numarası: 10.1007/s12013-026-02129-6
- Dergi Adı: CELL BIOCHEMISTRY AND BIOPHYSICS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE, Natural Science Collection (ProQuest), Biological Science Database (ProQuest), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Sayfa Sayıları: ss.4395-4407
- Anahtar Kelimeler: Angiogenesis, Drug resistance, Renal cell carcinoma, Succinic acid, Sunitinib-resistance
- İstanbul Üniversitesi Adresli: Evet
Özet
Drug resistance hinders treatment success in many cancers. Sunitinib is one of the first-line treatments in renal cell carcinoma (RCC), but resistance develops during treatment. By ameliorating their angiogenic ability, tumor cells finding a different route of escape in RCC is a majorconcern. We aimed to investigate the effects of the succinic acid sunitinib combination on the angiogenesis mechanism in sunitinib-resistant renal cancer cell lines. Gene expression levels of VEGF-A, VEGF-C, PDGF-A, HIF1A, TGF-beta, VHL, ANGPT1, and TIE2; protein levels of VEGF-A, HIF1A, and VHL were compared before, and after succinic acid-sunitinib combination treatment in ACHN cells that developed sunitinib resistance. In the sunitinib-resistant group, HIF1A, TGF-beta, ANGPT1, and TIE2 gene expression levels were significantly decreased with a combination therapy of succinic acid at 25 & micro;Mcompared to the resistant control group. Our study focused on clarifying the increase of angiogenic factors in sunitinib-resistant RCC cells following sunitinib treatment and the subsequent changes in the combination of succinic acid as a secondary treatment agent. It is also anticipated to guide future studies exploring the potential clinical application of the combination of sunitinib and succinic acid.